Literature DB >> 14962971

Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology.

P P Geusens, R N J de Nijs, W F Lems, R F J M Laan, A Struijs, T P van Staa, J W J Bijlsma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14962971      PMCID： PMC1754904          DOI： 10.1136/ard.2003.008060

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  14 in total

Review 1.  Glucocorticoid-induced osteoporosis: 2019 concise clinical review.

Authors:  G Adami; K G Saag
Journal:  Osteoporos Int       Date:  2019-02-25       Impact factor: 4.507

2.  EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Authors:  J N Hoes; J W G Jacobs; M Boers; D Boumpas; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; G Esselens; L Guillevin; I Hafstrom; J R Kirwan; J Rovensky; A Russell; K G Saag; B Svensson; R Westhovens; H Zeidler; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

Review 3.  Glucocorticoid-induced osteoporosis: who to treat with what agent?

Authors:  René Rizzoli; Emmanuel Biver
Journal:  Nat Rev Rheumatol       Date:  2014-11-11       Impact factor: 20.543

4.  Prevention and treatment of glucocorticoid-induced osteoporosis.

Authors:  Jeffrey R Curtis; Kenneth G Saag
Journal:  Curr Osteoporos Rep       Date:  2007-03       Impact factor: 5.096

Review 5.  Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures.

Authors:  Margaret Gourlay; Nora Franceschini; Yevgeniy Sheyn
Journal:  Clin Rheumatol       Date:  2006-05-03       Impact factor: 2.980

6.  Bone health in a tertiary-care gastroenterology and hepatology population.

Authors:  Millie D Long; Michelle T Thiny; Robert S Sandler; Lisa M Gangarosa
Journal:  Dig Dis Sci       Date:  2010-02-02       Impact factor: 3.199

Review 7.  Glucocorticoid-induced osteoporosis in rheumatic diseases.

Authors:  Rosa Maria Rodrigues Pereira; Jozélio Freire de Carvalho; Ernesto Canalis
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

8.  Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis.

Authors:  T Beukelman; K G Saag; J R Curtis; M L Kilgore; M Pisu
Journal:  Osteoporos Int       Date:  2009-11-24       Impact factor: 4.507

9.  Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.

Authors:  B L Langdahl; F Marin; E Shane; H Dobnig; J R Zanchetta; M Maricic; K Krohn; K See; M R Warner
Journal:  Osteoporos Int       Date:  2009-04-07       Impact factor: 4.507

Review 10.  Glucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment.

Authors:  Albrecht W Popp; Juerg Isenegger; Elizabeth M Buergi; Ulrich Buergi; Kurt Lippuner
Journal:  Eur Spine J       Date:  2006-07       Impact factor: 3.134
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.